Ceapro Announces Data from Research Collaboration with the 8-03-2023, 20:50

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Who really calls the shots at sea? New research sheds light on hidden ownership of the world’s industrial fishing fleets 21-05-2025, 14:01